Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Gaboxadol

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ovid pens deal to offload twice-failed former lead program
    Ovid pens deal to offload twice-failed former lead program

    09 Feb 2022

    // H. Shasteen BIOSPACE

    https://www.biospace.com/article/healx-and-ovid-therapeutics-enter-partnership-for-fragile-x-therapy/

    H. Shasteen BIOSPACE
    09 Feb 2022
    Share Share
    Ovid's Angelman syndrome therapy falls short at Phase 3
    Ovid's Angelman syndrome therapy falls short at Phase 3

    02 Dec 2020

    // PHARMAFILE

    http://www.pharmafile.com/news/565290/ovids-angelman-syndrome-therapy-falls-short-phase-3

    PHARMAFILE
    02 Dec 2020
    Share Share
    Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020
    Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020

    23 Nov 2020

    // PRESSRELEASE

    https://investors.ovidrx.com/news-releases/news-release-details/ovid-therapeutics-present-american-epilepsy-society-aes-2020

    PRESSRELEASE
    23 Nov 2020
    Share Share
    Angelini lands EU rights to Ovid's phase 3 rare disease drug
    Angelini lands EU rights to Ovid's phase 3 rare disease drug

    14 Jul 2020

    // Nick P Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/angelini-lands-eu-rights-to-ovid-s-phase-3-rare-disease-drug

    Nick P Taylor FIERCE BIOTECH
    14 Jul 2020
    Share Share
    Ovid Therapeutics Announces +ve Topline Results from Ph2 ROCKET Trial of OV101
    Ovid Therapeutics Announces +ve Topline Results from Ph2 ROCKET Trial of OV101

    08 May 2020

    // PRESS RELEASE

    https://investors.ovidrx.com/news-releases/news-release-details/ovid-therapeutics-announces-positive-topline-results-phase-2

    PRESS RELEASE
    08 May 2020
    Share Share